Norden Group
IONS icon

Norden Group’s Ionis Pharmaceuticals IONS Stock Holding History

Norden Group’s Portfolio IONS Stock Details IONS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		– Sell
-2,685
Closed -$213K – 711
2026
Q2 		$213K Sell
2,685
-204
-7% -$15.4K 0.02% 649
2026
Q1 		$217K Sell
2,889
-46
-2% -$3.63K 0.02% 572
2025
Q4 		$232K Buy
+2,935
New +$221K 0.02% 547

Other funds holding IONS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $106B AUM 32.76% 1-Year Est. Return
Tweedy, Browne Co
Tweedy, Browne Co Stamford, Connecticut $1.23B AUM 16.54% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return
GW&K Investment Management
GW&K Investment Management Boston, Massachusetts $11.8B AUM 29.45% 1-Year Est. Return
Squarepoint
Squarepoint New York $90.8B AUM 26.98% 1-Year Est. Return
Candriam SCA
Candriam SCA Strassen, Luxembourg, Luxembourg $22.5B AUM 50.38% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $420B AUM 34.97% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $500B AUM 36.84% 1-Year Est. Return

Norden Group's IONS Position: Q3 2026 in Review

Norden Group sold out of Ionis Pharmaceuticals (IONS) in Q3 2026, closing a stake of 2,685 shares — an estimated $213K sold.

Norden Group first reported a position in IONS in Q4 2025 and held it in 3 quarters. The position peaked at $232K in Q4 2025. 227 funds tracked by Wall St. Rank hold IONS as of Q3 2026.

  • Norden Group reported no remaining Ionis Pharmaceuticals position as of Q3 2026 after selling out during the quarter.
  • Norden Group sold 2,685 Ionis Pharmaceuticals shares in Q3 2026, an estimated $213K.
  • Norden Group first reported a position in Ionis Pharmaceuticals in Q4 2025 and held it in 3 quarters.
  • Norden Group's Ionis Pharmaceuticals position peaked at $232K in Q4 2025.
  • 227 funds tracked by Wall St. Rank held Ionis Pharmaceuticals as of Q3 2026.

Based on Norden Group's 13F filing for Q3 2026, filed 20 Oct 2026.